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Background/aim: Assessing the validity and clinical utility of axillary ultrasonography (AUS)-guided fine needle aspiration biopsy
(FNAB) in detection of nodal metastasis during preoperative axillary investigation in comparison to the histopathologic diagnosis in
early-stage breast cancer.
Materials and methods: A total of 279 operated primary breast cancer patients (age: 55.3 ± 12.8, ranged 17–90 years) were included.
Data on AUS findings at the time of initial diagnosis (first look AUS), second-look AUS findings performed by the breast radiologist
during breast biopsy procedure and the AUS-guided FNAB findings were evaluated with respect to the final histopathology report
obtained through axillary surgery via sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND). The diagnostic
performance of each method in detecting metastatic ALNs were compared in terms of sensitivity, specificity, accuracy, positive predictive
value (PPV), and negative predictive value (NPV).
Results: The sensitivity, specificity, and accuracy of the first look AUS in detecting nodal metastasis were 64.56%, 86.78%, and 74.19%
while the PPV and NPV were 86.44% and 65.22%, respectively. The sensitivity, specificity, and accuracy of the second-look AUS were
70.25%, 87.60%, and 77.78%, while PPV and NPV were 88.10% and 69.28%, respectively. The sensitivity, specificity, and accuracy of the
second-look AUS guided FNAB were 89.19%, 73.33%, and 87.30%, while the PPV and NPV were 96.12% and 47.83%, respectively. The
consideration of second-look AUS and finding of nodal metastasis in FNAB was associated with significantly higher likelihood of ALND
(55.4% vs. 44.6%, p < 0.001) and lower likelihood of SLNB (34.7% vs. 65.3%, p < 0.001) compared to consideration of nonmetastatic
ALN status. In 23 (22.3%) patients with positive findings on AUS-guided FNAB, SLNB was applied; 21 had positive results after surgical
dissection, indicating that nearly 20% of patients had unnecessary SLNB.
Conclusion: US-guided FNAB of suspicious ALNs is a simple, minimally invasive, and highly effective method for preoperative axillary
staging in patients with invasive breast cancer avoiding the more invasive method SLNB and it enables the surgeon to proceed directly
to ALND in positive cases.
Key words: Axillary ultrasonography, axillary dissection, breast cancer, fine needle aspiration biopsy, sentinel lymph node biopsy

1. Introduction
Axillary ultrasonography (AUS) is the primary imaging
modality for evaluating axillary lymph nodes (ALNs) and
its ability to identify the nodal metastases is considered
critical for staging, prognosis, and treatment of patients
with invasive breast cancer [1,2]. Preoperative axillary
investigation via axillary ultrasonography (AUS)-guided
fine needle aspiration biopsy (FNAB) has emerged as the

most practical minimally invasive method in this regard,
given its ability to confirm the presence of a metastasis in a
suspicious ALN, and thus to avoid the unnecessary invasive
sentinel lymph node biopsy (SLNB) and to allow nodepositive patients to proceed directly to axillary lymph node
dissection (ALND) as a single operative procedure [1-6].
In the clinical practice, while these “clinically nodepositive” patients undergo ALND without undergoing
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SLNB, “clinically node-negative” patients undergo SLNB
and those with negative results on SLNB has no further
axillary dissection since there is no survival benefit
for performing ALND in this setting [1,7]. SLNB was
developed as a method for axillary staging in early invasive
breast cancer which averts the unnecessary excision of
ALNs in patients with clinically node-negative disease
along with a high accuracy and a lower complication rate
compared with ALND [8-11]. However, it is a complex
laboratory technique with certain disadvantages such
as anaphylactic reactions, frozen section difficulties, a
longer operating time, and non-SLN skip metastasis along
with no node involvement beyond SLNs in considerable
portion breast cancer cases with positive SLNB have [1014]. In addition, while patients with positive SLNB results
traditionally undergo “completion” ALND, the role of
ALND in these patients is also being reassessed [1,15].
Hence, the main goal of the radiologist is to determine
the presence of metastatic disease in nonpalpable ALNs
to reveal clinically node-positive patients before surgery
by means of imaging with a positive predictive value that
is high enough to be useful to the surgeon in selecting
patients for upfront ALND or neo-adjuvant chemotherapy
without undergoing SLNB [1,7,10,16,17].
In the context of alternative methods to replace SLNB
with a decreasing role for axillary node dissection, USguided FNAB has become a promising minimally invasive
method in the accurate staging of the axilla with the
preoperative detection of nodal metastasis, while a need
for larger-scale and longer–follow-up comparative studies
has been emphasized [13,18,19].
This study aimed to assess the validity and clinical
utility of AUS- and US-guided FNAB in detection of nodal
metastasis during preoperative axillary investigation in
comparison to the final histopathologic results in earlystage breast cancer patients and to determine its impact on
the selection of ALND and/or SLNB by the surgeon.
2. Materials and methods
2.1. Study population
A total of 279 operated primary breast cancer patients
(mean ± SD age: 55.3 ± 12.8 years, ranged 17–90 years)
were included in this retrospective study conducted
between September 2014 and December 2018. Patients
who received preoperative neoadjuvant chemotherapy
and those without axillary histopathology report were
excluded from the study.
The study was conducted in accordance with the ethical
principles stated in the “Declaration of Helsinki” and
approved by the institutional ethics committee along with
the permission for the use of patient data for publication
purposes.

2.2. Assessments
Second-look AUS was performed during histopathological
examination of the primary breast tumor and FNAB was
performed to all patients with suspected lymph nodes.
In our study; lymph nodes with a short diameter greater
than 1 cm, a round shape, an indistinct fatty hilum, and
more than 3 mm of concentric or focal cortical thickening
were considered suspicious. Afterwards, all patients were
gone through axillary surgery for the final histopathologic
report. The patients with malignant FNAB underwent
SLNB and/or ALND at the time of definitive surgery,
while those with benign, suspicious, or insufficient FNABs
underwent SLNB using blue-dye and/or radio-colloid
injection.
Data on AUS findings at the time of initial diagnosis,
second-look AUS findings performed by the breast
radiologist to consider the need for axillary biopsy during
the primary breast tumor biopsy procedure, and the FNAB
findings were evaluated with respect to the final operative
histopathologic results. The diagnostic performance
of each method in detecting metastatic axillary lymph
nodes were compared in terms of sensitivity, specificity,
accuracy, positive predictive value (PPV), and negative
predictive value (NPV). By comparing the FNAB with
final histopathologic result, the rate of unnecessary SLNB
was estimated.
2.3. Statistical analysis
Statistical analysis was made using IBM SPSS Statistics
for Windows, version 23.0 (IBM Corp., Armonk, NY).
Pearson’s chi-squared test and Fisher’s exact test were
used for the comparison of categorical data. Data were
expressed as percent (%) and 95% confidence interval (CI)
where appropriate. p < 0.05 was considered statistically
significant.
3. Results
3.1. Baseline characteristics and diagnostic work-up
Invasive ductal carcinoma was the most common tumor
subtype, while the rates of luminal A and luminal
B molecular subtypes were 41.6% each. Nonbreastconserving surgery was applied in 67.0% of patients, while
axillary lymph node dissection and sentinel lymph node
dissection were applied in 48.4% and 27.6% of patients,
respectively (Table 1).
The nodal metastasis was considered in 42.3% of
patients by the first-look axillary US, in 45.1% of patients
by second-look AUS. Metastatic LAP was detected in
36.9% of patients who underwent FNAB. After axillary
SLNB and/or ALND, the presence of metastatic LAP was
histopathologically proven in 56.6% of patients (Table 1).
Final histopathologic report revealed the number of
benign and metastatic lymph node yield to be mean 8.84
± 6.15 (ranged 1 to 31) and 3.68 ± 2.69 (ranged 1 to 13),
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Table 1. Baseline characteristics and diagnostic work-up (n =
279).
Tumor subtype, n(%)
Invasive ductal carcinoma

224(80.3)

Mucinous carcinoma

7(2.5)

Invasive lobular carcinoma

8(2.9)

Invasive breast cancer

34(12.2)

Tubular cancer

3(1.1)

Ductal carcinoma in situ

2(0.7)

Solid papillary carcinoma

1(0.4)

Molecular sub-type, n(%)
Luminal A

116(41.6)

Luminal B

116(41.6)

Triple negative

21(7.5)

Her-2 +

26(9.3)

Surgery type, n(%)
Breast conserving surgery

92(33.0)

Nonbreast conserving surgery

187(67.0)

Lymph node dissection type, n(%)
Sentinel lymph node dissection

77(27.6)

Axillary lymph node dissection

135(48.4)

Both

67(24.0)

First-look axillary US, n(%)
Metastatic lymph node (-)

161(57.7)

Metastatic lymph node (+)

118(42.3)

Second look axillary US, n(%)
No need for biopsy

153(54.8)

FNAB performed

126(45.1)

Metastasis (-)

23(8.2)

Metastasis (+)

103(36.9)

Definite operative histology
Metastasis (-)

121(43.4)

Metastasis (+)

158(56.6)

respectively. Mean size of metastatic lymph nodes was
16.76 ± 7.81 (ranged 3–45) mm.
3.2. The diagnostic performance of first-look AUS with
respect to second-look AUS-guided FNAB decision
In 103 of 118 ALNs suspected of metastatic involvement
in the first-look AUS, the second-look AUS was required
with decision of FNAB. In 23 of 161 patients with ALNs
considered to be normal in the first-look AUS, secondlook AUS was required with decision of FNAB (Table 2).
The sensitivity, specificity and accuracy of the firstlook AUS in detecting the nodal metastasis were 81.75%,
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90.20%, and 86.38%, while the PPV and NPV were 87.29%
and 85.71%, respectively (Table 2).
3.3. The diagnostic performance of second-look AUS
with respect to FNAB findings
Of 126 patients who underwent FNAB after second-look
AUS, FNAB findings revealed nodal metastasis in 56.5%
of cases considered to be nonmetastatic in the second-look
AUS, while in 87.4% of cases considered to be metastatic
in the second-look AUS (Table 2).
The sensitivity, specificity and accuracy of the secondlook AUS in detecting nodal metastasis were 87.38%,
43.48%, and 79.37%, while the PPV and NPV were 87.38%
and 43.48%, respectively (Table 2).
3.4. Diagnostic performance of first-look AUS, secondlook AUS and FNAB with respect to definite operative
histology
The definite operative histology confirmed nodal
metastasis in 86.4% of 118 patients with suspicious ALNs
on initial AUS, in 88.1% of 126 patients with suspicious
ALNs in second-look AUS, and in 96.1% of 103 patients
with positive findings on FNAB (Table 3).
The definite operative histology confirmed nodal
metastasis in 34.8% of 161 cases considered to be not
metastatic in the first-look AUS, in 30.7% of 153 cases
considered not necessary to be evaluated via FNAB in
second-look AUS, and in 52.2% of 23 cases considered to
be not metastatic in FNAB (Table 3).
When compared to negative findings, the likelihood
of positive findings suggestive of metastasis in the firstlook AUS, second-look AUS, and FNAB was significantly
higher to reveal a nodal metastasis on definite operative
histology, overall (p < 0.001 for each) as well as in luminal
A (p < 0.001), luminal B (p < 0.001), triple negative (p =
0.009) subcategories (Table 3).
When compared to definite operative histology; the
sensitivity, specificity, and accuracy of the first-look AUS
in detecting nodal metastasis were 64.56%, 86.78%, and
74.19%, while the PPV and NPV were 86.44% and 65.22%,
respectively. The sensitivity, specificity, and accuracy of
the second-look AUS were 70.25%, 87.60%, and 77.78%,
while the PPV and NPV were 88.10% and 69.28%,
respectively. The sensitivity, specificity and accuracy of the
second-look AUS guided FNAB were 89.19%, 73.33%, and
87.30%, while the PPV and NPV were 96.12% and 47.83%,
respectively (Table 3).
3.5. The value of first-look AUS in selection of surgery
type and LN dissection method
Nonbreast-conserving surgery was significantly more
commonly selected for cases considered vs. not considered
to be metastatic during first-look AUS (74.6% vs. 61.5%,
p = 0.022). The sensitivity, specificity, and accuracy of
first-look AUS in selecting the surgery type were 44.06%,
67.39%, and 53.76%, respectively (Table 4).
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Table 2. Diagnostic performance of first-look axillary US with respect to second-look axillary US-guided FNAB decision and
performance of second-look US with respect to FNAB findings.
Second-look axillary USG, n(%) Diagnostic performance (%, 95% CI [min–max])
No biopsy

FNAB is
taken

p

PPV

<0.0011

87.29
85.71
81.75
90.20
86.38
(80.83–91.79) (80.51–89.71) (73.88–88.06) (84.35–94.41) (81.79–90.18)

NPV

Sensitivity

Specificity

Accuracy

First-look axillary AUS (n = 279)
Metastatic LN (–)
(n = 161)

138 (85.7)

Metastatic LN (+)
15 (12.7)
(n = 118)

23 (14.3)
103 (87.3)

FNAB findings, n(%)
Metastatic
LN (-)

Metastatic
LN (+)

Diagnostic performance (%, 95% CI [min-max])
p

PPV

0.0022

87.38
43.48
87.38
43.48
79.37
(82.76–90.89) (27.85–60.52) (79.38–93.11) (23.19–65.51) (71.25–86.06)

NPV

Sensitivity

Specificity

Accuracy

Second-look AUS (n = 126)
Metastatic LN (–)
(n = 23)

10 (43.5)

Metastatic LN (+)
13 (12.6)
(n = 123)

13 (56.5)
90 (87.4)

Note: AUS: axillary ultrasonography; LN: lymph node; FNAB: fine needle aspiration biopsy; PPV: positive predictive value; NPV:
negative predictive value; 1Pearson’s chi-squared test; 2Fisher’s exact test.

The consideration of nodal metastasis during first-look
AUS was associated with significantly higher likelihood of
ALND (70.3% vs. 32.3%, p < 0.001) and lower likelihood
of SLNB (5.1% vs. 44.1%, p < 0.001) compared to
consideration of nonmetastatic ALN status (Table 4).
3.6. The value of FNAB in selection of LN dissection
method
The consideration of second-look AUS and finding of
nodal metastasis in FNAB was associated with significantly
higher likelihood of ALND (55.4% vs. 44.6%, p < 0.001)
and lower likelihood of SLNB (34.7% vs. 65.3%, p < 0.001)
compared to consideration of nonmetastatic ALN status
(Table 4).
3.7. Unnecessary SLNB rate
In 23 (22.3%) of 103 patients with positive findings on
US guided FNAB, SLNB was applied. Of 23 patients with
SLNB, 21 (91.03%) had positive results after surgical
dissection, indicating that nearly 20% of patients had
unnecessary SLNB.
4. Discussion
The nodal metastasis rates obtained via first-look AUS
(42.3%), second-look AUS-guided FNAB (36.9%) and
the definite operative histology (56.6%) in our study were
consistent with the definite histopathology report in 86.4%,
88.1%, and 96.1% of initial predictions, respectively; while

US-guided FNAB was positive in 70.3% of cases with
definite pathology.
Similarly, in the study of Leenders et al., it was reported
that AUS showed suspicious lymph nodes in 28.4% cases,
FNAB showed axillary metastases in 32.7% of these LNs,
and the final histological analysis confirmed metastatic
disease in 37.3% of these suspected LNs [20]. Other
studies also reported that the US-guided FNAB identified
the structurally abnormal ALNs in 42.0% to 63.9% of
patients with positive final pathology [11,21-24]. Hence,
our findings support that US-guided lymph node sampling
via FNAB is a quick, well tolerated and indispensable
method of confirming the presence of a metastasis in a
node suspicious on imaging before the patient undergoes
ALND [1,6,16].
The sensitivity and specificity of second-look AUS
(70.25% and 87.60%) and FNAB (89.19% and 73.33%) in
the current study are in line with the reported ranges of
moderate sensitivity (25% to 87%) and a higher specificity
(77%–100%) for AUS-FNAB in the literature, supporting
that both sensitivity and specificity of AUS increases
when combined with FNAB and with selection of only
the ALNs deemed to be suspicious on AUS for aspiration
[4,16,17,19,20,25,26].
However, considering the definite operative histology
as a reference, the second-look AUS and FNAB revealed
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Table 3. Diagnostic performance of first-look AUS, second-look AUS and FNAB with respect to definite operative histology.
Definite operative histology

Diagnostic performance (%, 95% CI [min–max])

Metastatic Metastatic
p
LN (–)
LN (+)

PPV

NPV

Sensitivity

Specificity

Accuracy

First-look AUS (n = 279)
Metastatic LN –

105 (65.2) 56 (34.8)

Metastatic LN +

16 (13.6)

102 (86.4)

<0.0011

86.44
65.22
64.56
86.78
74.19
(79.92–91.08) (60.04–70.06) (56.56–71.99) (79.42–92.25) (68.64–79.23)

<0.0011

88.10
69.28
70.25
87.60
77.78
(80.01–92.31) (63.75–74.31) (62.47–77.25) (80.38–92.89) (72.44–82.52)

<0.0011

96.12
47.83
89.19
73.33
87.30
(91.43–98.29) (33.13–62.91) (81.19–94.29) (44.90–92.21) (80.20–92.56

<0.0011

84.78
75.71
69.64
88.33
79.31
(73.11–91.95) (67.48–82.41) (55.90–81.22) (77.43–95.18) (70.80–86.27)

<0.0011

93.75
57.35
60.81
92.86
72.41
(82.23–97.84) (50.01–64.39) (48.77–71.96) (80.52–98.50) (63.34–80.30)

0.0092

83.33
77.78
83.33
77.78
80.95
(58.93–94.57) (48.51–92.86) (51.59–97.91) (39.99–97.19) (58.09–94.55)

0.7012

–

Second-look AUS (n = 279)
No biopsy
Biopsy is taken
(metastasis)
FNAB (n = 126)

106 (69.3) 47 (30.7)
15 (11.9)

111 (88.1)

Metastatic LN –

11 (47.8)

12 (52.2)

Metastatic LN +

4 (3.9)

99 (96.1)

Luminal A- ALN prediction (n = 116)
Metastatic LN –

53 (75.7)

17 (24.3)

Metastatic LN +

7 (15.2)

39 (84.8)

Luminal B- ALN prediction (n = 116)
Metastatic LN –

39 (57.4)

29 (42.6)

Metastatic LN +

3 (6.3)

45 (93.8)

Triple negative- A LN prediction (n = 21)
Metastatic LN –

7 (77.8)

2 (22.2)

Metastatic LN +

2 (16.7)

10 (83.3)

Her-2 positive (n = 26)
Metastatic LN –

6 (42.9)

8 (57.1)

Metastatic LN +

4 (33.3)

8 (66.7)

–

–

–

–

Note: AUS: axillary ultrasonography; ALN: axillary lymph node; FNAB: fine needle aspiration biopsy; PPV: positive predictive value;
NPV: negative predictive value; 1Pearson’s chi-squared test; 2Fisher’s exact test.

false-negative results in 30.7% and 52.2% of our cases,
respectively. Hence, AUS-guided FNAB was associated
a PPV of 96.12% but an NPV of 47.83%, supporting the
previously reported low NPV (ranged 59.3% to 73.0%) and
high false negativity (ranged 19.4% to 31.8%) of this method
in detecting ALN metastases [10,11,13,17,20,27,28]. Given
that the negative AUS-FNAB revealed nonmetastatic
axillae only in half of our patients, our findings seem to
support that AUS-FNAB alone is not likely to be relied
upon in axillary investigation to replace SLNB for the
time being due to moderate sensitivity and the high falsenegative rate [17,20].
The sampling error, micrometastasis, and errors in
radiologic and pathologic assessment are considered
to be the possible causes of false-negative results
[11,17,18,22,29,30], while the sensitivity of AUS-FNAB is
also suggested to increase with tumor size [5,10,31-33]. The
average size of metastatic lymph nodes (16.76 mm, ranged
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3 to 45 mm) in the current study seems notable in this
regard, given the higher probability of metastases >0.5 mm
than small metastases (<0.5 mm) to be detected by FNAB
(%93 vs. 44%) [30]. Indeed, while the false-negativity of
AUS-FNAB is especially detected in lymph nodes with
micrometastases or isolated tumor cells, the necessity of
ALND in such situations remains also controversial [17].
Notably, in a past study with 27 early-stage breast cancer
patients, FNAB in comparison with SLNB was reported to
have a sensitivity, specificity, PPV and NPV of 45%, 100%,
100%, and 73%, respectively [13]. The authors concluded
the similar specificity of FNAB-based and SLNB-based
ALN cytology in the presence of ALN metastases, whereas
lower sensitivity of FNAB than SLNB when lymph node
cytology is negative, indicating that negative AUS-FNAB
results do not rule out the metastatic implants [13,34].
In contrary, for patients with preoperative identification
of positive AUS and AUS-guided FNAB, the need for
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Table 4. The value of first-look AUS and second-look AUS-guided FNAB in selection of surgery and/or LN dissection method.
Type of surgery, n (%)
Breast
Non-breast
p
conserving conserving

Diagnostic performance (%, 95% CI [min–max])
PPV

NPV

Sensitivity

Specificity

Accuracy

First-look AUS (n = 279)
Metastatic LN (–),
62 (38.5)
no biopsy (n = 161)

99 (61.5)

Metastatic LN (+)
(n = 118)

88 (74.6)a

30 (25.4)

<0.0221 74.58
38.51
44.06
67.39
53.76
(67.82–80.33) (33.98–43.25) (39.74–54.48) (56.82–76.80)
(47.72–59.73)

LN dissection method, n(%)
SLNB

p

ALND

First-look AUS (n≠2279)
Metastatic LN (–)
(n≠2161)

109 (54.8)

Metastatic LN (+)
(n≠2118)

35 (23.8)

90 (45.2)
<0.0011

76.19
54.77
(70.05–81.41) (50.3–59.17)

<0.0011

81.45
54.50
50.00
84.03
64.16
(74.66–86.75) (50.64–58.32) (42.90–57.10) (77.00–89.60) (58.86–69.22)

112 (76.2)a

55.45
75.69
63.87
(48.31–62.42) (67.85–82.45) (58.56–68.94)

Second look-US and FNAB findings
Metastatic LN (–),
121 (54.5)
no biopsy (n≠2176)

101 (45.5)

Metastatic LN (+)
(n≠2103)

101 (81.5)

23 (18.5 )

a

Note: AUS: axillary ultrasonography; SLNB: sentinel lymph node biopsy; ALND: axillary lymph node dissection; FNAB: fine needle
aspiration biopsy; PPV: positive predictive value; NPV: negative predictive value; aUsed as true positive; 1Pearson’s chi-squared test;
2
Some patients have both surgeries.

SLNB is considered likely to be eliminated; thus, AUSguided positive FNAB is suggested to allow patients to be
triaged to ALND, bypassing the potentially unnecessary
SLNB [1,11,35].
Likewise, our findings indicated the increased likelihood
of ALND rather than SNLB to be considered for a ALN
found metastatic on a second-look USG guided FNAB, while
in nearly 20% of patients who had been initially positive for
AUS-FNAB, the SLNB revealed positive findings. Hence,
indicating the primary role of radiologist by providing
accurate AUS guidance for FNAB, our findings emphasize
that the unnecessary SNLBs can be avoided in at least one
fifth of node-positive patients with primary breast cancer
via preoperative AUS-FNAB-based axillary investigation.
This supports the consideration of node positive group to
benefit most from axillary FNAB with consequent reduction
of SLNB [6,17,20,36] and that positive AUS-FNAB can
spare SLND and enable the surgeon to proceed directly
with ALND in 8%–28% of breast cancer patients [19,20,25].
In a past study, the authors reported US-guided FNAB
positivity in 821 of 1152 patients which resulted in avoiding
11.7% of patients to undergo needless SLNB [37]. Likewise,
a metaanalysis of 31 studies on 2397 AUS-guided biopsies

(FNAC and core biopsies) of ALNs in breast cancer patients
revealed a sensitivity of 75.0% and a specificity of 98.5%
along with 19.8% rate of women triaged directly to ALND
[38]. Also, in a systematic review of studies in breast cancer
patients, the unnecessary SLNBs were reported to be
avoided in 1%–28% of patients with preoperative axillary
FNAB [39].
In a prospective study including 100 female patients
with breast cancer, the overall AUS-FNAB sensitivity was
reported to be 79.4% with PPV and NPV of 100% and
69.5%, respectively, while the AUS-FNAB sensitivity was
0% for lymph nodes with normal sonographic features, 80%
for indeterminate lymph nodes and 90.5% for suspicious
lymph nodes [2]. The authors concluded that AUS should
be included in the preoperative staging of all patients with
invasive breast cancer, while addition of FNAB to AUS in
cases of lymph nodes suspicious for malignancy could avoid
SLNB in 54% of cases, significantly shortening the time
interval to definitive therapy [2].
The increased likelihood of ALND rather than SNLB
in cases with second-look AUS-guided FNAB positivity
compared to those with negative FNAB findings in the
current study seems notable given the consideration
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of an abnormal AUS and positive FNAB to correlate
with patients eligible for ALND as well as with a higher
nodal burden on final pathology compared with patients
with metastasis identified on SLNB [19]. Indeed, while
AUS-guided FNAB has been considered to be useful in
diagnosing lymph node metastases and triaging breast
cancer patients directly to ALND, there is a trend toward
less aggressive axillary surgery with ongoing controversy
regarding the role of ALND in sentinel node-positive
women due to emerging evidence indicating no survival
benefit of completion ALND in early breast cancer patients
with node-positive disease [1,20,40-44].
Given its association with lower false-negative rate
than the AUS-FNAB, the AUS-guided core needle biopsy
(CNB) has also become an increasingly more popular
approach of axillary staging in breast cancer patients which
avoids SLNB and a second trip to the operating room
[1]. Nonetheless, in a metaanalysis of 67 studies on USFNAB and CNB of ALNs in patients with breast cancer,
a diagnostic test accuracy revealed that CNB showed
higher sensitivity than US-FNAC (0.849 vs. 0.760), while
there was no difference in specificity between US-FNAC
and CNB (0.997 vs. 1.000) [45]. The authors concluded
that both US-FNAC and CNB are useful in preoperative
assessments of ALNs in patients with breast cancer [45].
The FNAB positivity in 56.5% of AUS negative cases
in the current study seems also notable given that AUSFNAB is performed for only patients with suspicious ALN
on AUS and the use of US-FNAB for nonsuspicious ALNs
is considered to be associated with classification of these
cases as true negatives [45]. Hence, studies addressing the
comparison of the diagnostic accuracy between suspicious
and nonsuspicious subgroups in AUS are considered
to be useful for improving the diagnostic accuracy of
preoperative assessments of ALNs and lowering the falsenegative rate of AUS and AUS-FNAB [45].
Notably, in a study among 101 patients including those
with positive AUS-FNAB and corresponding ALND (n =
65) and those with negative US-FNA with corresponding
ALND/SLNB (n = 36), 43% of patients in the positive USFNA group were reported to have two or fewer positive

lymph nodes upon ALND pathologic examination
(indicating the risk of overtreatment) [46]. The authors
also reported the NPV of detecting axillary disease was
83.3% in the AUS-FNAB negative group, indicating the
possibility of undertreatment in 16.7% of patients [46].
The comparative analysis between US-FNA and SLNB
showed that performing US-FNA resulted in a reduction
in SLNB reaching 40%, avoiding an additional surgical
procedure, and reducing the cost by up to 20% [4,46-48].
The retrospective single-center design of the present
study seems to be the major limitation that prevents the
establishing temporality between the cause and effect as
well as generalizing our findings to overall breast cancer
population.
In conclusion, US-guided FNAB of suspicious ALNs is
a simple, minimally invasive and highly effective method
for preoperative axillary staging in patients with invasive
breast cancer that can identify those patients with high
metastatic nodal burden and thus potentially avoid SLNB
and enable the surgeon to proceed directly to ALND in
positive cases.
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